Search Results - "Woyach, J.A."

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL by Woyach, Jennifer A, Ruppert, Amy S, Heerema, Nyla A, Zhao, Weiqiang, Booth, Allison M, Ding, Wei, Bartlett, Nancy L, Brander, Danielle M, Barr, Paul M, Rogers, Kerry A, Parikh, Sameer A, Coutre, Steven, Hurria, Arti, Brown, Jennifer R, Lozanski, Gerard, Blachly, James S, Ozer, Hatice G, Major-Elechi, Brittny, Fruth, Briant, Nattam, Sreenivasa, Larson, Richard A, Erba, Harry, Litzow, Mark, Owen, Carolyn, Kuzma, Charles, Abramson, Jeremy S, Little, Richard F, Smith, Scott E, Stone, Richard M, Mandrekar, Sumithra J, Byrd, John C

“…Among older patients with untreated chronic lymphocytic leukemia, treatment with ibrutinib, either alone or in combination with rituximab, was superior to…”
Get full text

Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force by Stauder, R., Eichhorst, B., Hamaker, M.E., Kaplanov, K., Morrison, V.A., Österborg, A., Poddubnaya, I., Woyach, J.A., Shanafelt, T., Smolej, L., Ysebaert, L., Goede, V.

“…Chronic lymphocytic leukemia (CLL) mainly affects older people: the median age at diagnosis is > 70 years. Elderly patients with CLL are heterogeneous with…”
Get full text

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia by Rogers, K A, Ruppert, A S, Bingman, A, Andritsos, L A, Awan, F T, Blum, K A, Flynn, J M, Jaglowski, S M, Lozanski, G, Maddocks, K J, Byrd, J C, Woyach, J A, Jones, J A

“…Chronic lymphocytic leukemia (CLL) is frequently complicated by secondary autoimmune cytopenias (AICs). Ibrutinib is an irreversible inhibitor of Bruton’s…”
Get full text

Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia by Ruppert, A.S., Yin, J., Davidian, M., Tsiatis, A.A., Byrd, J.C., Woyach, J.A., Mandrekar, S.J.

“…Ibrutinib therapy is safe and effective in patients with chronic lymphocytic leukemia (CLL). Currently, ibrutinib is administered continuously until disease…”
Get full text

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features by Woyach, J A, Lozanski, G, Ruppert, A S, Lozanski, A, Blum, K A, Jones, J A, Flynn, J M, Johnson, A J, Grever, M R, Heerema, N A, Byrd, J C

Get full text

PF377 ACALABRUTINIB WITH OBINUTUZUMAB IN TREATMENT‐NAIVE AND RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: 3‐YEAR FOLLOW‐UP by Woyach, J.A., Rogers, K., Bhat, S., Blachly, J., Jianfar, M., Frigault, M.M., Hamdy, A., Izumi, R., Munugalavadla, V., Quah, C., Wang, M.H., Byrd, J.C.

“…Background: Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor. Aims: This Phase 1b/2 trial evaluated acalabrutinib with…”
Get full text

Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol by Blum, K A, Ruppert, A S, Woyach, J A, Jones, J A, Andritsos, L, Flynn, J M, Rovin, B, Villalona-Calero, M, Ji, J, Phelps, M, Johnson, A J, Grever, M R, Byrd, J C

“…Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor,…”
Get full text

A phase I II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma by Woyach, J A, Lin, T S, Lucas, M S, Heerema, N, Moran, M E, Cheney, C, Lucas, D M, Wei, L, Caligiuri, M A, Byrd, J C

“…Rituximab has modest activity in relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma but is associated with tumor necrosis factor-α (TNF-α)…”
Get full text